|
Human Gene Therapy
Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions
To cite this article:
Marybeth S. Hughes, Yik Y.L. Yu, Mark E. Dudley, Zhili Zheng, Paul F. Robbins, Yong Li, John Wunderlich, Robert G. Hawley, Morvarid Moayeri, Steven A. Rosenberg, Richard A. Morgan.
Human Gene Therapy.
April 2005,
16(4): 457-472.
doi:10.1089/hum.2005.16.457.
Published in Volume: 16 Issue 4: May 4, 2005
Marybeth S. Hughes Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Yik Y.L. Yu Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Mark E. Dudley Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Zhili Zheng Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Paul F. Robbins Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Yong Li Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. John Wunderlich Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Robert G. Hawley Hematopoiesis Department, Holland Laboratory, American Red Cross, Rockville, MD, 20855. Morvarid Moayeri Hematopoiesis Department, Holland Laboratory, American Red Cross, Rockville, MD, 20855. Steven A. Rosenberg Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Richard A. Morgan Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. The genes for the α and β chains of a highly reactive anti-MART-1 T-cell receptor were isolated from T-lymphocytes that mediated in vivo regression of tumor in a patient with metastatic melanoma. These genes were cloned and inserted into MSCV-based retroviral vectors. After transduction, greater than 50% gene transfer efficiency was demonstrated in primary T-lymphocytes stimulated by an anti-CD3 antibody. The specificity and biologic activity of TCR gene-transduced T-cells was determined by cytokine production after coculture of T-cells with stimulator cells pulsed with MART-1 peptide. The production of interferon-γ and granulocyte macrophage-colony stimulating factor (GM-CSF) was comparable to highly active MART-1 specific peripheral blood lymphocytes (PBL) in the amount of cytokine produced and transduced cells recognized peptide pulsed cells at dilutions similar to cytotoxic T lymphocyte (CTL) clones. Human leukocyte antigen (HLA) class I restricted recognition was demonstrated by mobilization of degranulation marker CD107a, by cell lysis, by cytokine production, and by proliferation in the presence of HLA-A2–positive but not HLA-A2–negative melanoma cell lines. Similar data was obtained when tumor-infiltrating lymphocytes (TIL) were transduced with the TCR genes, converting previously nonreactive cells to tumor reactive cells. TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer.  This paper was cited by:Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity P D Peng, C J Cohen, S Yang, C Hsu, S Jones, Y Zhao, Z Zheng, S A Rosenberg, R A Morgan Gene Therapy. Jul 2009 CrossRef Lentiviral Vector Design for Optimal T Cell Receptor Gene Expression in the Transduction of Peripheral Blood Lymphocytes and Tumor-Infiltrating Lymphocytes Stephanie Jones, Peter D. Peng, Shicheng Yang, Cary Hsu, Cyrille J. Cohen, Yangbing Zhao, John Abad, Zhili Zheng, Steven A. Rosenberg, Richard A. Morgan Human Gene Therapy. Jun 2009, Vol. 20, No. 6: 630-640 Abstract | Full Text PDF | Reprints & PermissionsTCR transgenes and transgene cassettes for TCR gene therapy: status in 2008 Wolfgang Uckert, Ton N. M. Schumacher Cancer Immunology, Immunotherapy. Jun 2009, Vol. 58, No. 5: 809-822 CrossRef Adoptive Immunotherapy of Disseminated Leukemia With TCR-transduced, CD8+ T Cells Expressing a Known Endogenous TCR Michelle L Dossett, Ryan M Teague, Thomas M Schmitt, Xiaoxia Tan, Laurence JN Cooper, Cristina Pinzon, Philip D Greenberg Molecular Therapy. May 2009, Vol. 17, No. 4: 742-749 CrossRef Gibbon Ape Leukemia Virus Poorly Replicates in Primary Human T Lymphocytes Cor H. J. Lamers, Ralph A. Willemsen, Pascal M. M. L. van Elzakker, Jan Willem Gratama, Reno Debets Journal of Immunotherapy. May 2009, Vol. 32, No. 3: 272-279 CrossRef Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression Jennifer A. Wargo, Paul F. Robbins, Yong Li, Yangbing Zhao, Mona El-Gamil, Diana Caragacianu, Zhili Zheng, Julie A. Hong, Stephanie Downey, David S. Schrump, Steven A. Rosenberg, Richard A. Morgan Cancer Immunology, Immunotherapy. Apr 2009, Vol. 58, No. 3: 383-394 CrossRef Combinatorial Incorporation of Enhancer-Blocking Components of the Chicken β-Globin 5′HS4 and Human T-Cell Receptor α/δ BEAD-1 Insulators in Self-Inactivating Retroviral Vectors Reduces Their Genotoxic Potential Ali Ramezani, Teresa S. Hawley, Robert G. Hawley Stem Cells. Jan 2009, Vol. 26, No. 12: 3257-3266 CrossRef Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated Cells Shicheng Yang, Steven A. Rosenberg, Richard A. Morgan Journal of Immunotherapy. Dec 2008, Vol. 31, No. 9: 830-839 CrossRef Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition S Yang, C J Cohen, P D Peng, Y Zhao, L Cassard, Z Yu, Z Zheng, S Jones, N P Restifo, S A Rosenberg, R A Morgan Gene Therapy. Dec 2008, Vol. 15, No. 21: 1411-1423 CrossRef Adoptive cell transfer: a clinical path to effective cancer immunotherapy Steven A. Rosenberg, Nicholas P. Restifo, James C. Yang, Richard A. Morgan, Mark E. Dudley Nature Reviews Cancer. May 2008, Vol. 8, No. 4: 299-308 CrossRef T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model John D. Abad, Claudia Wrzensinski, Willem Overwijk, Moniek A. De Witte, Annelies Jorritsma, Cary Hsu, Luca Gattinoni, Cyrille J. Cohen, Chrystal M. Paulos, Douglas C. Palmer, John B. A. G. Haanen, Ton N. M. Schumacher, Steven A. Rosenberg, Nicholas P. Restifo, Richard A. Morgan Journal of Immunotherapy. Feb 2008, Vol. 31, No. 1: 1-6 CrossRef A T cell receptor associated with naturally occurring human tumor immunity B. D. Santomasso, W. K. Roberts, A. Thomas, T. Williams, N. E. Blachere, M. E. Dudley, A. N. Houghton, J. B. Posner, R. B. Darnell Proceedings of the National Academy of Sciences. Dec 2007, Vol. 104, No. 48: 19073-19078 CrossRef Selecting highly affine and well-expressed TCRs for gene therapy of melanoma A. Jorritsma, R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. N. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. M. Schumacher, J. B. A. G. Haanen Blood. Dec 2007, Vol. 110, No. 10: 3564-3572 CrossRef Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Pawel Muranski, Andrea Boni, Claudia Wrzesinski, Deborah E Citrin, Steven A Rosenberg, Richard Childs, Nicholas P Restifo Nature Clinical Practice Oncology. Jan 2007, Vol. 3, No. 12: 668-681 CrossRef Transduction of an HLA-DP4???restricted NY-ESO-1???specific TCR into Primary Human CD4+ Lymphocytes Yangbing Zhao, Zhili Zheng, Hung T. Khong, Steven A. Rosenberg, Richard A. Morgan Journal of Immunotherapy. Aug 2006, Vol. 29, No. 4: 398-406 CrossRef Avenues for immunomodulation and graft protection by gene therapy in transplantation Daniel J. Moore, James F. Markmann, Shaoping Deng Transplant International. Jul 2006, Vol. 19, No. 6: 435-445 CrossRef Adoptive immunotherapy for cancer: building on success Luca Gattinoni, Daniel J. Powell, Steven A. Rosenberg, Nicholas P. Restifo Nature Reviews Immunology. Jun 2006, Vol. 6, No. 5: 383-393 CrossRef Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8+ T cells and the suppressive effects of tolerogenic dendritic cells Shin-ichiro Fujii, Michael I. Nishimura, Michael T. Lotze Cancer Science. Jan 2006, Vol. 96, No. 12: 897-902 CrossRef Update on cancer vaccines Freda K Stevenson Current Opinion in Oncology. Dec 2005, Vol. 17, No. 6: 573-577 CrossRef
|
|